Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.56 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644088 | 1.00 | SLC6A4 (0.66) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL30504080 | 0.90 | SLC6A4 (0.59) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL30124921 | 0.90 | SMPD1 (0.59) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL30601752 | 0.90 | SMPD1 (0.59) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL2060462 | 0.90 | SMPD1 (0.59) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL1447864 | 0.90 | SLC6A4 (0.59) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL15726115 | 0.87 | SLC6A4 (0.54) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL22636179 | 0.87 | SLC6A4 (0.54) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL17049367 | 0.87 | CCR5 (0.56) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL4434864 | 0.87 | SLC6A4 (0.56) | SLC6A4MAOBCCR5ALDH1A1USP28 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473264-B2 | Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2023171231-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | キヤノン株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-116075512-A | Heterocyclic compounds and imaging agents for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023056102-A1 | NOVEL PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | ATAI Life Sciences AG (DE) | 2023-04-06 | — | — | WO | disclosed |
| US-20220388968-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2022-12-08 | — | — | US | disclosed |
| EP-3534903-B1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| WO-2020257495-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3534903-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2818531-B1 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2818531-B1 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9567526-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| EP-2818531-A1 | Polymerisable compounds and the use thereof in liquid-crystal displays | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140375943-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| CN-103080056-A | Method for preparing hydroxytyrosol by using organic metal compound | LONZA AG | 2013-05-01 | — | — | CN | disclosed |
| WO-2012006783-A1 | PROCESS FOR PRODUCTION OF HYDROXYTYROSOL USING ORGANOMETALLIC COMPOUNDS | LONZA LTD (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-4046901-A | HYPOTENSIVE AGENTS | ROUSSEL-UCLAF (FR) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | COMT, PNMT, ABCB1 | SLC6A4 29/4885MAOB 28/4885CCR5 3678/4885 |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | SLC6A4 2531/4885MAOB 212/4885CCR5 84/4885 |
| US-20220388968-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | SPTBN1, CTTN, HBG1 | SLC6A4 4331/4885MAOB 3013/4885CCR5 3630/4885 |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | SLC6A4 2531/4885MAOB 212/4885CCR5 84/4885 |
| US-12473264-B2 | Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof | HBG1, SPTBN1, CTTN | SLC6A4 4161/4885MAOB 2588/4885CCR5 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.